However, two extensive epidemiological studies indicate that the first occurrences of immune TTP are not heightened by SARS-CoV-2 vaccination, but may trigger acute bouts of relapses of immune TTP in individuals with a severely deficient ADAMTS13 activity who are asymptomatic [56,57]. The gene discussed is ADAMTS13; the disease is thrombotic thrombocytopenic purpura.